MITF-Independent Pro-Survival Role of BRG1-Containing SWI/SNF Complex in Melanoma Cells

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Ondrušová, Lubica ^a   Vachtenheim, Jiri ^a   Réda, Jiri ^a   Žáková, Petra ^a   Benková, Kamila ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BRG1 PROTEIN; BRM PROTEIN; CYCLIN DEPENDENT KINASE 2; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; OSTEOPONTIN; PROTEIN SWI; SOMATOMEDIN C; SURVIVIN; TRANSCRIPTION FACTOR SNF; TRANSFORMING GROWTH FACTOR BETA2;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; COLONY FORMATION; COMPLEX FORMATION; CONTROLLED STUDY; GENE CONTROL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MELANOMA CELL; MICROARRAY ANALYSIS; PLASMID; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOMAL PROTEINS, NON-HISTONE; CYCLIN-DEPENDENT KINASE 2; DNA HELICASES; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; NEVUS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPONTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA2;

EID: 84872578727     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054110     Document Type: Article

References (56)

1. Chin L, Garraway LA, Fisher DE, (2006) Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 20: 2149-2182.
2. Miller AJ, Mihm MC Jr, (2006) Melanoma. N Engl J Med 355: 51-65.
3. Goding CR, (2000) Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev 14: 1712-1728.
4. Levy C, Khaled M, Fisher DE, (2006) MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 12: 406-414.
5. Vachtenheim J, Borovansky J, (2010) "Transcription physiology" of pigment formation in melanocytes: central role of MITF. Exp Dermatol 19: 617-627.
6. Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, et al. (2004) Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6: 565-576.
7. Carreira S, Goodall J, Aksan I, La Rocca SA, Galibert MD, et al. (2005) Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 433: 764-769.
8. McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, et al. (2002) Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109: 707-718.
9. Dynek JN, Chan SM, Liu J, Zha J, Fairbrother WJ, et al. (2008) Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. Cancer Res 68: 3124-3132.
10. Carreira S, Goodall J, Denat L, Rodriguez M, Nuciforo P, et al. (2006) Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev 20: 3426-3439.
11. Goodall J, Carreira S, Denat L, Kobi D, Davidson I, et al. (2008) Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. Cancer Res 68: 7788-7794.
12. Roberts CW, Orkin SH, (2004) The SWI/SNF complex-chromatin and cancer. Nat Rev Cancer 4: 133-142.
13. Halliday GM, Bock VL, Moloney FJ, Lyons JG, (2009) SWI/SNF: a chromatin-remodelling complex with a role in carcinogenesis. Int J Biochem Cell Biol 41: 725-728.
14. Reisman D, Glaros S, Thompson EA, (2009) The SWI/SNF complex and cancer. Oncogene 28: 1653-1668.
15. Versteege I, Sevenet N, Lange J, Rousseau-Merck MF, Ambros P, et al. (1998) Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394: 203-206.
16. Medina PP, Romero OA, Kohno T, Montuenga LM, Pio R, et al. (2008) Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat 29: 617-622.
17. Glaros S, Cirrincione GM, Muchardt C, Kleer CG, Michael CW, et al. (2007) The reversible epigenetic silencing of BRM: implications for clinical targeted therapy. Oncogene 26: 7058-7066.
18. Reisman DN, Sciarrotta J, Wang W, Funkhouser WK, Weissman BE, (2003) Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res 63: 560-566.
19. Fukuoka J, Fujii T, Shih JH, Dracheva T, Meerzaman D, et al. (2004) Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res 10: 4314-4324.
20. Dunaief JL, Strober BE, Guha S, Khavari PA, Alin K, et al. (1994) The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell 79: 119-130.
21. Bartlett C, Orvis TJ, Rosson GS, Weissman BE, (2011) BRG1 mutations found in human cancer cell lines inactivate Rb-mediated cell-cycle arrest. J Cell Physiol 226: 1989-1997.
22. Sentani K, Oue N, Kondo H, Kuraoka K, Motoshita J, et al. (2001) Increased expression but not genetic alteration of BRG1, a component of the SWI/SNF complex, is associated with the advanced stage of human gastric carcinomas. Pathobiology 69: 315-320.
23. Sun A, Tawfik O, Gayed B, Thrasher JB, Hoestje S, et al. (2007) Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. Prostate 67: 203-213.
24. de la Serna I, Ohkawa Y, Higashi C, Dutta C, Osias J, et al. (2006) The microphthalmia-associated transcription factor requires SWI/SNF enzymes to activate melanocyte-specific genes. J Biol Chem 281: 20233-20241.
25. Keenen B, Qi H, Saladi SV, Yeung M, de lS I, (2010) Heterogeneous SWI/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma. Oncogene 29: 81-92.
26. Vachtenheim J, Ondrusova L, Borovansky J, (2010) SWI/SNF chromatin remodeling complex is critical for the expression of microphthalmia-associated transcription factor in melanoma cells. Biochem Biophys Res Commun 392: 454-459.
27. Saladi SV, Marathe H, de lS I, (2010) SWItching on the transcriptional circuitry in melanoma. Epigenetics 5: 469-475.
28. Lin H, Wong RP, Martinka M, Li G, (2010) BRG1 expression is increased in human cutaneous melanoma. Br J Dermatol 163: 502-510.
29. Saladi SV, Keenen B, Marathe HG, Qi H, Chin KV, et al. (2010) Modulation of extracellular matrix/adhesion molecule expression by BRG1 is associated with increased melanoma invasiveness. Mol Cancer 9: 280.
30. Liu T, Brouha B, Grossman D, (2004) Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene 23: 39-48.
31. Busca R, Berra E, Gaggioli C, Khaled M, Bille K, et al. (2005) Hypoxia-inducible factor 1{alpha} is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J Cell Biol 170: 49-59.
32. McGill GG, Haq R, Nishimura EK, Fisher DE, (2006) c-Met expression is regulated by Mitf in the melanocyte lineage. J Biol Chem 281: 10365-10373.
33. Vachtenheim J, Novotna H, Ghanem G, (2001) Transcriptional repression of the microphthalmia gene in melanoma cells correlates with the unresponsiveness of target genes to ectopic microphthalmia-associated transcription factor. J Invest Dermatol 117: 1505-1511.
34. Zhou Y, Dai DL, Martinka M, Su M, Zhang Y, et al. (2005) Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 124: 1044-1052.
35. Hilmi C, Larribere L, Giuliano S, Bille K, Ortonne JP, et al. (2008) IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin. J Invest Dermatol 128: 1499-1505.
36. Javelaud D, Alexaki VI, Mauviel A, (2008) Transforming growth factor-beta in cutaneous melanoma. Pigment Cell Melanoma Res 21: 123-132.
37. Pierrat MJ, Marsaud V, Mauviel A, Javelaud D (2012) Expression of Microphtalmia-Associated Transcription Factor (MITF), which is Critical for Melanoma Progression, is Inhibited by both Transcription Factor GLI2 and Transforming Growth Factor-beta. J Biol Chem.
38. Zhang C, Zhang F, Tsan R, Fidler IJ, (2009) Transforming growth factor-beta2 is a molecular determinant for site-specific melanoma metastasis in the brain. Cancer Res 69: 828-835.
39. Peltonen S, Hentula M, Hagg P, Yla-Outinen H, Tuukkanen J, et al. (1999) A novel component of epidermal cell-matrix and cell-cell contacts: transmembrane protein type XIII collagen. J Invest Dermatol 113: 635-642.
40. Das S, Harris LG, Metge BJ, Liu S, Riker AI, et al. (2009) The hedgehog pathway transcription factor, GLI1 promotes malignant behavior of cancer cells by upregulating osteopontin. J Biol Chem.
41. Vachtenheim J, Drdova B, (2004) A dominant negative mutant of microphthalmia transcription factor (MITF) lacking two transactivation domains suppresses transcription mediated by wild type MITF and a hyperactive MITF derivative. Pigment Cell Res 17: 43-50.
42. Xu Y, Zhang J, Chen X, (2007) The activity of p53 is differentially regulated by Brm- and Brg1-containing SWI/SNF chromatin remodeling complexes. J Biol Chem 282: 37429-37435.
43. Flowers S, Nagl NG Jr, Beck GR Jr, Moran E, (2009) Antagonistic roles for BRM and BRG1 SWI/SNF complexes in differentiation. J Biol Chem 284: 10067-10075.
44. Bourgo RJ, Siddiqui H, Fox S, Solomon D, Sansam CG, et al. (2009) SWI/SNF deficiency results in aberrant chromatin organization, mitotic failure, and diminished proliferative capacity. Mol Biol Cell 20: 3192-3199.
45. Strobeck MW, Reisman DN, Gunawardena RW, Betz BL, Angus SP, et al. (2002) Compensation of BRG-1 function by Brm: insight into the role of the core SWI-SNF subunits in retinoblastoma tumor suppressor signaling. J Biol Chem 277: 4782-4789.
46. Bandyopadhyay D, Curry JL, Lin Q, Richards HW, Chen D, et al. (2007) Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi. Aging Cell 6: 577-591.
47. Shen H, Powers N, Saini N, Comstock CE, Sharma A, et al. (2008) The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. Cancer Res 68: 10154-10162.
48. Yamamichi N, Inada K, Ichinose M, Yamamichi-Nishina M, Mizutani T, et al. (2007) Frequent loss of Brm expression in gastric cancer correlates with histologic features and differentiation state. Cancer Res 67: 10727-10735.
49. Becker TM, Haferkamp S, Dijkstra MK, Scurr LL, Frausto M, et al. (2009) The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a. Mol Cancer 8: 4.
50. Kido K, Sumimoto H, Asada S, Okada SM, Yaguchi T, et al. (2009) Simultaneous suppression of MITF and BRAF V600E enhanced inhibition of melanoma cell proliferation. Cancer Sci 100: 1863-1869.
51. Vaisanen T, Vaisanen MR, Autio-Harmainen H, Pihlajaniemi T, (2005) Type XIII collagen expression is induced during malignant transformation in various epithelial and mesenchymal tumours. J Pathol 207: 324-335.
52. Ohanna M, Giuliano S, Bonet C, Imbert V, Hofman V, et al. (2011) Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev 25: 1245-1261.
53. Giuliano S, Cheli Y, Ohanna M, Bonet C, Beuret L, et al. (2010) Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas. Cancer Res 70: 3813-3822.
54. Stecca B, Mas C, Clement V, Zbinden M, Correa R, et al. (2007) Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci U S A 104: 5895-5900.
55. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, et al. (2012) A landscape of driver mutations in melanoma. Cell 150: 251-263.
56. Watanabe H, Mizutani T, Haraguchi T, Yamamichi N, Minoguchi S, et al. (2006) SWI/SNF complex is essential for NRSF-mediated suppression of neuronal genes in human nonsmall cell lung carcinoma cell lines. Oncogene 25: 470-479.